Page last updated: 2024-12-10

(endo-n-8-methyl-8-azabicyclo-(3.2.1)oct-3-yl)-2,3-dihydro-3-isopropyl-2-oxo-1h-benzimidazol-1-carboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

You're asking about a compound with a very specific name: **(endo-N-8-methyl-8-azabicyclo-(3.2.1)oct-3-yl)-2,3-dihydro-3-isopropyl-2-oxo-1H-benzimidazol-1-carboxamide**. This name describes a complex molecule with a specific structure.

**Here's a breakdown of what it means:**

* **(endo-N-8-methyl-8-azabicyclo-(3.2.1)oct-3-yl)**: This part describes a bicyclic ring system with nitrogen (N) and a methyl group attached.
* endo refers to the position of the substituent on the bicyclic ring.
* 8-azabicyclo-(3.2.1)oct indicates the ring system with a nitrogen atom and specific carbon counts in the rings.
* **2,3-dihydro-3-isopropyl-2-oxo-1H-benzimidazol-1-carboxamide**: This describes another ring system, a benzimidazole, with various substituents.
* 2,3-dihydro indicates that there are two hydrogen atoms attached to the benzimidazole ring.
* 3-isopropyl means that an isopropyl group is attached at the third position.
* 2-oxo signifies a carbonyl group (C=O) at the second position.
* 1H indicates a hydrogen atom at the first position.
* 1-carboxamide indicates a carboxamide group (-CONHâ‚‚) attached at the first position.

**Importance in Research**

This specific compound might be important for research due to its potential biological activity. Here's why:

* **Molecular Structure:** The complex structure of this molecule is likely designed to interact with specific biological targets, potentially proteins or enzymes.
* **Benzimidazole Core:** Benzimidazole derivatives are known to have diverse biological activities, including antimicrobial, antiviral, and anti-cancer properties.
* **Bicyclic System:** The bicyclic system might contribute to the molecule's interaction with specific receptors or enzymes.
* **Potential Therapeutic Applications:** The specific combination of these structural features could lead to potential therapeutic applications.

**To determine its exact importance in research, you would need more information.** For example:

* **Is it a known drug?** If it's a drug, it would have a specific target and therapeutic applications.
* **Is it a lead compound?** If it's a lead compound, it's likely being studied for its potential therapeutic effects.
* **Is it a research tool?** It might be used as a tool to study specific biological processes or targets.

To find more information about this compound, you could search online databases like PubChem or Google Scholar using its full chemical name.

(endo-N-8-methyl-8-azabicyclo-(3.2.1)oct-3-yl)-2,3-dihydro-3-isopropyl-2-oxo-1H-benzimidazol-1-carboxamide: potent agonist at the 5-HT(4) receptor positively coupled to adenylate cyclase in brain; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5311028
SCHEMBL ID10322633
SCHEMBL ID7634797
MeSH IDM0191256

Synonyms (17)

Synonym
bimu8
bimu 8
(endo-n-8-methyl-8-azabicyclo-(3.2.1)oct-3-yl)-2,3-dihydro-3-isopropyl-2-oxo-1h-benzimidazol-1-carboxamide
bimu-8
1h-benzimidazole-1-carboxamide, 2,3-dihydro-n-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-3-(1-methylethyl)-2-oxo-, monohydrochloride, endo-
134296-40-5
SCHEMBL10322633
2,3-dihydro-n-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-3-(1-methylethyl)-2-oxo-1h-benzimidazole-1-carboxamide hydrochloride
SCHEMBL7634797
AKOS024458124
J-006511
DTXSID80895072
Q4835690
n-[(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-3-propan-2-ylbenzimidazole-1-carboxamide;hydrochloride
MS-26191
2,3-dihydro-n-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-3-(1-methylethyl)-2-oxo-1h-benzimidazole-1-carboxamidehydrochloride
AKOS040744952
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's16 (59.26)18.2507
2000's4 (14.81)29.6817
2010's5 (18.52)24.3611
2020's2 (7.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (96.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]